Humana Financial Insights Q2 2025

Humana Q2 2025 beat expectations with strong CenterWell Pharmacy and MA growth. Raised EPS outlook to ~$17; focus on MA, efficiency, and shareholder returns.
Humana Q2 2025 beat expectations with strong CenterWell Pharmacy and MA growth. Raised EPS outlook to ~$17; focus on MA, efficiency, and shareholder returns.
This website uses cookies to ensure you get the best experience on our website.